FIRMAGON® (degarelix for injection) IS APPROVED FOR ALL STAGES OF ADVANCED PROSTATE CANCER (APC)
≈60% OF PATIENTS IN THE CLINICAL TRIAL HAD LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER2
The pivotal CS21 study included men aged ≥18 years with histologically confirmed adenocarcinoma of the prostate (all stages), for whom endocrine treatment was indicated (except for neoadjuvant therapy).2
In the clinical trials, these categories were classified as “other.”2
START FIRMAGON® TODAY
2014: >16,500 patients started on FIRMAGON
2015: >10% increase in starts over 20143
Help make the most of your patient's treatment experienceMake the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.
Abbreviations: ADT = androgen deprivation therapy; APC = advanced prostate cancer; PSA = prostate-specific antigen.
REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.3. Data on file. Ferring Pharmaceuticals Inc.